Mereo BioPharma to Present at the Jefferies Healthcare Conference
May 31, 2023 07:00 ET
|
Mereo BioPharma Group plc
LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
May 23, 2023 13:43 ET
|
Mereo BioPharma Group plc
LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced...
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 08, 2023 12:46 ET
|
Mereo BioPharma Group plc
LONDON, May 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
May 05, 2023 16:06 ET
|
Mereo BioPharma Group plc
LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
April 13, 2023 08:00 ET
|
Mereo BioPharma Group plc
LONDON, April 13, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
March 28, 2023 16:30 ET
|
Mereo BioPharma Group plc
LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
March 21, 2023 06:30 ET
|
Mereo BioPharma Group plc
Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU No additional...
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
February 08, 2023 07:00 ET
|
Mereo BioPharma Group plc
LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 08, 2022 07:00 ET
|
Mereo BioPharma Group plc
LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
November 02, 2022 16:01 ET
|
Mereo BioPharma Group plc
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases,...